Mesoblast Celebrates FDA Approval and Launch of Ryoncil® as a Milestone in Cellular Medicine
Mesoblast Limited, a biotechnology company, has announced its financial results and operational updates, highlighting the successful FDA approval and commercial launch of its product Ryoncil, a treatment for steroid-refractory acute graft-versus-hos…
3 minutes to read